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Introduction
Systemic treatment of advanced metastatic melanoma has been an unmet medical need for decades. Chemotherapy with dacarbazine or other cytotoxic drugs resulted in median survival times of 7e9 months and no therapeutic regimen, either other chemotherapeutic agents, biochemotherapy, or immunotherapy proved to be superior to dacarbazine in terms of survival [1] . In these times, long-term survival of 5 years and more was only achieved in 5e10% of patients regardless of the specific therapy strategy used. Recently, during the last few years, the treatment of metastatic melanoma has been rapidly evolving. Approximately 40e50% of metastatic cutaneous melanomas harbour a BRAF V600 mutation, constitutively activating the mitogen-activated protein kinase (MAPK) pathway [2] . The BRAF inhibitors vemurafenib and dabrafenib were developed to specifically target this driver mutation and further similar compounds like encorafenib are still under study [3, 4] . Another target is the signalling molecule MEK downstream of BRAF, and its blockade can likewise inactivate the MAPK pathway [5] . Both, BRAF and MEK inhibitors showed superior activity in BRAF V600-mutated melanoma in comparison to dacarbazine, and led to a significantly increased progression-free (PFS) and overall survival (OS) in the respective patients. Even more efficacious is the combined inhibition of both targets, BRAF and MEK, and thus a simultaneous application of vemurafenib plus cobimetinib or dabrafenib plus trametinib led to a further prolongation of PFS and OS [6e9].
New immunotherapeutic approaches for metastatic melanoma are another promising approach, which developed simultaneously and in parallel to MAPK pathway inhibitors, resulting in two separate novel treatment strategies. Presently, targeting immune checkpoints, which normally terminate immune responses after antigen activation, is a main focus in the treatment of advanced melanoma. Cytotoxic Tlymphocyte-associated antigen-4 (CTLA-4) is an immunomodulatory molecule that down-regulates Tcell-activation. Ipilimumab, a fully human monoclonal antibody that blocks CTLA-4 was the first successfully developed drug of a new class of therapeutics named immune checkpoint inhibitors. Long-term survival of up to 20% of treated patients has been reported with ipilimumab [10e12]. Programmed-death-1 (PD1) is another immune checkpoint target expressed on activated T-cells mediating immunosuppression. Its ligands PD-L1 (B7-H8) and PD-L2 (B7-DC) are expressed on many tumour cells, stroma cells and other cell types including leucocytes. The immunosuppressive action of the PD1 receptor is activated in the effector phase of the interaction between T lymphocytes and tumour cells, and the blockade of this receptor seems to be more effective towards T-cell-activation than CTLA-4 blockade. Nivolumab (BMS-936558) is a fully human IgG4 monoclonal antibody directed against PD1. Pembrolizumab (MK-3475) is a selective, humanised monoclonal IgG4-kappa anti-PD1 antibody. The efficacy of both agents was studied in advanced melanoma and other solid tumours [13e15]. Other PD-1 and PD-L1 inhibitors are also under evaluation.
With regard to these new developments in the treatment of advanced melanoma, only few of these therapies have yet been compared to one another, and trials have not yet been conducted to evaluate the optimal sequence of therapies with rigorous, randomised designs. For BRAF-mutant patients, multiple therapy strategies with documented survival improvement exist from which to choose. However, there are no clear data as to which regimen should be administered in the first, second, or even third line, or whether there are patient characteristics or biomarkers helpful for treatment selection.
This work analyses selected clinical trials representative for the new treatment strategies in advanced melanoma and compares their survival outcome by digitisation of published KaplaneMeier survival curves. [5] . Comparator therapy arms confounded by cross-over to experimental arms were omitted from analysis due to a mixed therapeutic situation.
Description of survival curves
KaplaneMeier survival curves for PFS and OS, respectively, were identified from the publications of the selected clinical trials, and subsequently scanned, extracted, and manually digitised using an interactive digitising software (DigitizeIt; http://www.DigitizeIt.de/ ). This software creates sampling points and allows curve construction by linear interpolation between these points. The accuracy of the manual digitisation depends on the quality of the graphical displays in the respective publications and on the zoom factors necessary for enlarging the displays. This method allows the construct of mean KaplaneMeier curves by averaging selected groups of individual KaplaneMeier plots. Weighted averaging is performed point-wise at the sampling points t k from all individual KaplaneMeier plots b S i ðtÞ in the group G by weighing with sample sizes n i :
Description of survival proportions
From each available KaplaneMeier curve we calculated the proportion of patients free of disease progression at 6 months (6-months-PFS), and alive at 12 months (12-months-OS), respectively. For the estimation of variability we used a formula suggested by Peto [16] for an unbiased approximate estimate for the standard error (SE) for the survival distribution S(t):
C(t) equals the number of effectively censored data up to the time point t; N is the number of patients at study start. The empirical SE can be achieved by replacing S(t) by its empirical b SðtÞ. A two-sided approximate confidence interval for S(t) can be based on a normal approximation and would thus read 
1=2
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Results

Explorative analysis of survival outcomes
Thirty-five KaplaneMeier curves for either PFS or OS or both were available from the publications of 17 clinical trials selected by the above mentioned criteria (Table  1  and  Supplementary  Table  1 ) [3,4,6e9,11,12,14,15,18e26] . After digitisation, the survival curves were newly grouped and displayed by treatment line (first-line versus second or later lines) and therapy strategy (chemotherapy, single-agent BRAF inhibitor therapy, combination BRAF plus MEK inhibitor therapy, CTLA-4 inhibitor therapy, PD1 inhibitor therapy, combination CTLA-4 plus PD1 inhibitor therapy), respectively (Supplementary Figs. 1 and 2 ), to allow a head-to-head explorative comparison. Trials including first-as well as second-line therapy were grouped as second-line trials.
Grouping of digitised KaplaneMeier survival curves by therapy strategy showed a high concordance between the single survival curves within each group ( Supplementary Figs. 1 and 2 ). This high concordance was found even in therapy strategy groups containing different agents, e.g. for CTLA-4 inhibitors (ipilimumab, tremelimumab), PD1 inhibitors (nivolumab, pembrolizumab), and BRAF inhibitors (vemurafenib, dabrafenib), respectively. Weighted averaging of survival curves was performed within each group as described above and displayed separately for first-line therapies as well as for later therapy lines (Fig. 1) . For first-line therapy strategy groups, averaged survival proportions (percentages of PFS at 6 months and OS at 12 months, respectively) were calculated and displayed in Supplementary Table 2.
Survival with MAPK pathway inhibitors
Mean survival curves obtained by weighted averaging revealed the combination treatment with BRAF plus MEK inhibitors clearly superior to BRAF inhibition alone in first-line treatment PFS and OS as well as in second-line or later PFS (Fig. 1AeC) . The proportions of patients free of disease progression at 6 months were 71.6% with BRAF plus MEK inhibition compared to 56.0% with BRAF inhibition alone; the proportions of patients alive at 12 months were 74.5% compared to 64.4% (Supplementary Table 2 ). Second-line or later OS data for BRAF plus MEK inhibitor combination Data were taken from publications of the respective clinical trials, besides a. a, proportions of patients free of disease progression at six months, and alive at twelve months, respectively, were calculated from Kaplan-Meier survival curves as described in Materials and Methods. Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; mo, months; n.d., not done and/or not reported in publication; n.a., not applicable. 6   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62 therapy were not available at the time point of this analysis (Fig. 1D) . BRAF inhibitor monotherapy led to better survival outcomes than chemotherapy in first-line treatment PFS (proportions of patients free of disease progression at 6 months 56.0% versus 22.1%; Supplementary Table 2 ) and OS (proportions of patients alive at 12 months 64.4% versus 42.2%; Supplementary Table 2) (Fig. 1A, B) . In second-line or later therapy settings no chemotherapy arms were used in recent clinical trials; thus no survival data were available for the PFS and OS explorative analysis (Fig. 1C, D) .
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Survival with immune checkpoint blockers
PD-1 inhibitors revealed a better survival outcome than CTLA-4 inhibitors in all therapy settings, first-line PFS and OS as well as second-line or later PFS and OS, as obtained by weighted averaging (Fig. 1AeD) . For the first-line setting, the proportions of patients free of disease progression at 6 months were 51.0% with PD-1 inhibitors compared to 31.0% with CTLA-4 inhibitors; the proportions of patients alive at 12 months were 71.9% compared to 50.1% (Supplementary Table 2 ). PD-1 plus CTLA-4 inhibitor combination therapy showed better survival data than PD-1 inhibitors alone in first-line PFS (proportions of patients free of disease progression at 6 months 63.8% versus 51.0%, Supplementary Table 2; Fig. 1A ). For all other therapy settings up to now no survival data have been available for this combination (Fig. 1BeD) . CTLA-4 inhibition resulted in an improved survival compared to chemotherapy, at least for first-line treatment PFS and OS (Fig. 1A, B) . The proportions of patients free of disease progression at 6 months were 31.0% with CTLA-4 inhibition versus 22.1% with chemotherapy; the proportions of patients alive at 12 months were 50.1% versus 42.2% (Supplementary Table 2 ). For the secondline setting, no survival data under chemotherapy were available (Fig. 1C, D) .
Comparison of survival with MAPK pathway inhibitors and immune checkpoint blockers
In first-line therapy, weighted averaging revealed superior survival curves for the MAPK pathway blockade with BRAF plus MEK inhibitor combination therapy compared to immune checkpoint blockade with PD-1 inhibitors alone (PFS, OS; Fig. 1A, B) or in combination with CTLA-4 (PFS; Fig. 1A) . The proportions of patients free of disease progression at 6 months were 71.6% with BRAF plus MEK inhibition compared to 63.8% with CTLA-4 plus PD-1 inhibition and 51.0% with PD-1 inhibition alone, respectively (Supplementary Table 2 ). This superiority of BRAF plus MEK 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 inhibition versus immune checkpoint blockers is clearly visible during the first year after onset of treatment, thereafter curves are crossing and the survival outcomes of these treatment strategies roughly equal. Accordingly, the proportions of patients alive at 12 months were 74.5% with BRAF plus MEK inhibitor treatment versus 71.9% with PD-1 blockade (Supplementary Table 2 ).
In the second-line setting, weighted average PFS curves revealed a superiority of BRAF plus MEK inhibitor combination therapy compared to PD-1 inhibition (Fig. 1C) . For OS in this setting, up to now no data are available for the combination therapy (Fig. 1D) . Survival under BRAF inhibitor monotherapy was superior to that under CTLA-4 inhibition. This difference in survival was more obvious in the first-line setting (Fig. 1A, B ) than in the second or later lines (Fig. 1C,  D) . PFS and OS under BRAF inhibitor monotherapy is superior to that under PD-1 inhibitor therapy within the first 6 months of first-line therapy (Fig. 1A, B) . After this time period, survival curves cross, and PD-1 inhibitor therapy reveals a better long-term survival compared to BRAF inhibition. In the second-line or later setting, weighted average survival curves of both treatment strategies, BRAF and PD-1 inhibitor monotherapy, run equally during the first 3e6 months of treatment (Fig. 1C, D) . Thereafter, PD-1 inhibition clearly shows superior long-term survival in both, PFS and OS, as compared with single-agent BRAF inhibition.
Discussion
A tremendous improvement in the survival of advanced metastatic melanoma patients has been achieved by the recently developed therapy strategies of kinase inhibitors as well as immune checkpoint blockers. In this regard, combination regimens of BRAF and MEK inhibitors proved to be superior to single-agent regimens with BRAF inhibitors. Within the group of immune checkpoint blockers, the first head-to-head comparative trials (KEYNOTE-006; CheckMate-067) demonstrated the PD-1 inhibitors to prolong survival as compared to CTLA-4 inhibition with ipilimumab [24] . Moreover, for PFS the combination treatment with PD1 inhibitors plus ipilimumab tends to be superior to PD1 inhibition alone, at least in certain patient subgroups (CheckMate-067; CheckMate-069) [26] . For OS there are no data yet available for evaluation.
However, there still are no data available from clinical trials testing BRAF and/or MEK inhibitors headto-head with checkpoint blockers. In this regard, our presentation of KaplaneMeier survival curves grouped by matching inclusion criteria, and superimposed by weighted averaging shows clear and informative trends. Using this methodology, we found that the combination of BRAF plus MEK inhibitors provides very similar results in terms of survival as PD1 inhibition as a singleagent or in combination with ipilimumab. These two treatment strategies, BRAF plus MEK inhibition and PD1 plus or minus CTLA-4 inhibition, were superior to all other therapy modalities investigated. Interestingly, this superiority became evident in PFS and OS in the first-line as well as in second and later-line settings. The second best survival curves resulted from single-agent BRAF inhibitor therapies, which were clearly inferior to BRAF plus MEK inhibitor combinations, and also to PD1 inhibitors, respectively. The poorest survival was observed with single-agent ipilimumab and with any type of chemotherapy, respectively, with ipilimumab showing slightly better results than chemotherapy.
Importantly, due to the rapid development of new therapeutics, times of study conduct are of high probability to impact survival outcomes in melanoma patients. In specific, the availability of subsequent treatments which could prolong OS differed during the last years; e.g. many BRAF inhibitor trials were conducted before PD1 blockers became available. It should also be noted, that long-term follow-up data are only available for ipilimumab to indicate that the same 20% of patients alive at 3 years are alive at 5 years and beyond [10] . This longevity of benefit has yet to be established for PD-1 or BRAF inhibitor-based treatments. Since the clinical use of ipilimumab started much earlier than that of PD1 blockers, long-term survival data for anti-PD1 of 3 years and longer are not yet available.
Finally, it should be noted, that the results of this descriptive comparative analysis have to be interpreted with caution. In general, the inclusion criteria of the different trials were similar (no active or untreated brain metastases, no ocular primary, ECOG Q3 performance state 0 or 1), Supplementary Table 1. However, differences in these criteria were present, such as a different definition of brain metastasis control or the possibility to treat beyond progression. These deviations between trials may have led to different patient selections, and thus may have influenced patient's survival outcomes. Additionally, the percentages of patients with poor prognostic markers like elevated serum LDH
Q4
, impaired overall performance status, or higher M category, differed significantly between trials even if their inclusion criteria were similar (Supplementary Table 1 ). Due to the descriptive nature of the comparisons done by us, no statistical tests were applied.
The conclusions drawn from clear differences between survival curves resulting from different treatment strategies allow a first preliminary transfer into the routine clinical setting of decision-making in advanced metastatic melanoma patients. Notably, the survival curves taken from single clinical trials and grouped by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 distinct therapy strategies revealed a very high concordance, even if different agents were used. However, to confirm these first trends for implementation into an individualised treatment of melanoma patients, data from prospective clinical trials comparing the different treatment strategies head-to-head have to be awaited. From our perspective, this explorative comparison showing the combination of BRAF and MEK kinase inhibitors as similarly effective as PD1 immune checkpoint blockade towards survival, although of limited validity, highlights the good performance of the targeted therapy approach based on BRAF kinase inhibitors in advanced melanoma. This is of special importance in the current times where immunotherapy dominates the therapeutic field of advanced melanoma. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26   27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50 
